Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease

Published:2024-06-13 Issue:25 Volume:18 Page:16297-16311
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Park Byeongmin¹²,Han Geonhee¹³,Jin Do Young⁴,Gil Ki Cheol¹³,Shin Dongwon¹³,Lee Jongwon¹³,Park Jung Yeon³,Jang Hochung¹⁵,Park Daeho¹,Lee Sangmin²^ORCID,Kim Kwangmeyung⁶^ORCID,Yang Yoosoo¹⁵^ORCID,Kim Yongju³^ORCID,Kim Jun-Seob⁴^ORCID,Kim Sun Hwa¹³,Shim Man Kyu¹^ORCID

Affiliation:

1. Medicinal Materials Research Center, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea

2. College of Pharmacy, Graduate School of Pharmaceutical Sciences, Kyung Hee University, Seoul 02453, Republic of Korea

3. KU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea

4. Department of Nano-Bioengineering, Incheon National University, Incheon 22012, Republic of Korea

5. Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Republic of Korea

6. College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea

Funder

National Research Foundation of Korea

Korea Institute of Science and Technology

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.4c05544

Reference54 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease

2. Response to biologic therapy in Crohnʼs disease is improved with early treatment: An analysis of health claims data

3. Gut microbial metabolism of 5-ASA diminishes its clinical efficacy in inflammatory bowel disease

4. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

5. Top-down therapy for IBD: rationale and requisite evidence

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in novel functionalized oral administration therapy for inflammatory bowel diseases;Chinese Science Bulletin;2024-08-01